Medibank Private Ltd hits new all-time high: Should you buy?

Yesterday, after competitor NIB Holdings Limited (ASX: NHF) announced a 20% profit upgrade for the year, shares of Medibank Private Ltd (ASX: MPL) also shot higher, reaching a new 52-week high of $3.20 before closing at $3.17.

It seems Medibank buyers are hoping that a similar decrease in claim expenses is waiting in the wings for shareholders. With premium (i.e. revenue) increases regulated by the government and the industry itself highly competitive, one of the most effective ways to boost profits is to cut expenses. Medibank has recently experienced some success in this area.

Prospective Medibank buyers should be cautious of NIB’s announcement however, since in the past the small company has been able to grow its policyholder numbers at competitors’ expense. With Medibank the top dog in the health insurance market, its customer base is a fat target for competitors.

Still not a bargain

Medibank has already told the market that it expects a weaker second half, and its first half profits were inflated by 10% thanks to a $20 million one-off tax benefit. This makes it appear less likely that the company will surprise investors, yet even if it was set to report substantially lower claim expenses, Medibank does not look cheap.

If we exclude the one-off tax benefit and double half-year profit to approximate full-year results, Medibank trades on a price to earnings (P/E) ratio in the mid-20s, which is quite high for an insurer.

With legislated premium increases every year it is possible to construct an attractive investment thesis, but factor in customer policy downgrades, recent loss of market share, the uncertainty of a new CEO and several other factors and I can’t be certain that Medibank will be a winning investment at today’s prices.

The business itself is solid and I would not sell if I was a shareholder. However, I’m not confident that Medibank today is a significantly better buy than other opportunities out there.

Discover the 'new breed' of blue chips that could take your portfolio higher in 2016

Forget about health insurers - these 3 "new breed" top blue chips for 2016 pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to learn more.

This report is completely free - no credit card required. What are you waiting for?

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.